Pulmonary arterial hypertension and lung transplantation

2011 ◽  
Vol 5 (3) ◽  
pp. 441-454 ◽  
Author(s):  
James L Lordan ◽  
Paul A Corris
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Lung Transplantation ◽  
Pulmonary Arterial

Navigating the Road to Transplant in Pulmonary Arterial Hypertension: A Road Less Taken

2016 ◽  
Vol 15 (1) ◽  
pp. 12-13
Author(s):  
Adaani E. Frost ◽  
Harrison W. Farber
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Lung Transplantation ◽  
Small Cell ◽  
Small Cell Lung ◽  
Donor Organ ◽  
The Road ◽  
Lung Allocation Score ◽  
Pulmonary Arterial

Dramatic advances in therapy for pulmonary arterial hypertension (PAH) in the last 20 years have improved survival from a median of 2.5 years in the pretreatment era to 7.5 years currently. However, impressive as that may seem, it is important to note that a median survival of 7.5 years is equivalent to that of surgically resected non-small cell lung cancer, thus underscoring the importance of lung transplantation as a treatment option in patients with PAH. In this edition of Advances, Edelman has reviewed the pathway to transplantation for patients with PAH, detailing the recommendations for timing of referral, listing for lung transplantation, the role of the lung allocation score in allocating a donor organ, and the outcome of lung transplantation.

scholarly journals Heart and lung transplantation in pulmonary arterial hypertension related to congenital heart disease: an unusual indication

2020 ◽  
Vol 4 (S1) ◽  
Author(s):  
Rosaria Barracano ◽  
Heba Nashat ◽  
Andrew Constantine ◽  
Konstantinos Dimopoulos
Keyword(s):  
Pulmonary Hypertension ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Lung Transplantation ◽  
Atrial Septal Defect ◽  
Septal Defect ◽  
Pulmonary Vascular Disease ◽  
Eisenmenger Syndrome ◽  
Pulmonary Arterial ◽  
Recurrent Haemoptysis

Abstract Background Eisenmenger syndrome is a multisystem disorder, characterised by a significant cardiac defect, severe pulmonary hypertension and long-standing cyanosis. Despite the availability of pulmonary hypertension therapies and improved supportive care in specialist centres, Eisenmenger patients are still faced with significant morbidity and mortality. Case presentation We describe the case of a 44-year-old woman with Eisenmenger syndrome secondary to a large secundum atrial septal defect. Her pulmonary vascular disease was treated with pulmonary vasodilators, but she experienced a progressive decline in exercise tolerance, increasing atrial arrhythmias, resulting in referral for transplantation. Her condition was complicated by significant recurrent haemoptysis in the context of extremely dilated pulmonary arteries and in-situ thrombosis, which prompted successful heart and lung transplantation. She made a slow recovery but remains well 3 years post-transplant. Conclusions Patients with Eisenmenger syndrome secondary to a pre-tricuspid lesion, such as an atrial septal defect have a natural history that differs to patients with post-tricuspid shunts; the disease tends to present later in life but is more aggressive, prompting early and aggressive medical intervention with pulmonary arterial hypertension therapies. This case illustrates that severe recurrent haemoptysis can be an indication for expediting transplantation in Eisenmenger syndrome patients.

Lung transplantation in pulmonary arterial hypertension

ESC CardioMed ◽  
2018 ◽  
pp. 2520-2524
Author(s):  
Laurent Savale
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Lung Transplantation ◽  
Medical Management ◽  
Life Support ◽  
Extracorporeal Life Support ◽  
Right Heart Failure ◽  
Optimal Timing ◽  
Optimal Medical Management ◽  
Pulmonary Arterial

Despite recent advances in medical management, lung and heart–lung transplantation remains an established treatment option in patients with end-stage pulmonary arterial hypertension (PAH) despite optimal medical therapy. The optimal timing of referral and listing patients for transplantation must take into consideration the co-morbidities, the aetiology of PAH, and the regular risk assessment based on a multidimensional approach. With the exception of PAH due to complex congenital heart disease, double-lung transplantation is the preferred option over combined heart–lung transplantation as cardiac function recovers after transplantation in most cases. The use of extracorporeal life support as a bridge to urgent transplantation may be considered in expert centres in selected patients with refractory right heart failure despite optimal medical management in an intensive care unit. With a survival rate at 5 years varying from 50% to 75%, transplantation in PAH can be considered as a life-saving procedure for patients with severe symptoms.

scholarly journals Nocturnal hypercapnia with daytime normocapnia in patients with advanced pulmonary arterial hypertension awaiting lung transplantation

PLoS ONE ◽  
2020 ◽  
Vol 15 (4) ◽  
pp. e0227775
Author(s):  
Yoshinari Nakatsuka ◽  
Toyofumi Chen-Yoshikawa ◽  
Hideyuki Kinoshita ◽  
Akihiro Aoyama ◽  
Hiroyasu Kubo ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Lung Transplantation ◽  
Pulmonary Arterial
Sign in / Sign up

Export Citation Format

Share Document